Frontiers in Sports and Active Living · Oct 30, 2026
Lifestyle Interventions and Adipokine Dysregulation in Individuals with Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
By Jiamu Li, jinwei Zhao, Yu Wu et al.
Background:Metabolic syndrome (MetS) describes a cardiometabolic risk state in which multiple metabolic abnormalities coexist, often alongside visceral adiposity, insulin resistance, and adipose-tissue dysfunction. Lifestyle interventions may alter circulating adipokine concentrations, but randomized trial evidence in clinically defined MetS remains inconsistent.Objective: This study synthesized randomized trial evidence on the effects of lifestyle interventions on circulating adipokines in individuals with clinically defined MetS. Methods: We searched PubMed/MEDLINE, Embase, Scopus, Web of Science Core Collection, and the CENTRAL from inception through June 1, 2026. Eligible studies were randomized controlled trials of exercise, dietary, or combined lifestyle interventions in participants with MetS defined according to recognized diagnostic criteria. Primary outcomes were circulating adiponectin and leptin; secondary and exploratory outcomes included omentin-1, resistin, visfatin, retinol-binding protein 4, and other reported adipokines. Random-effects meta-analyses were performed using the DerSimonian–Laird estimator for between-study variance, with effects expressed as weighted mean differences (WMDs) or standardized mean differences (SMDs), depending on outcome comparability; 95% prediction intervals (PIs) were calculated for the primary outcomes. Risk of bias was assessed using the Cochrane RoB 2 tool, and outcome-specific certainty of evidence was graded using GRADE.Results:The review included 25 reports describing 23 unique randomized controlled trials. Lifestyle interventions were associated with higher adiponectin concentrations (WMD 0.85 μg/mL, 95% CI 0.14 to 1.55; I² = 70.1%; 95% PI −1.83 to 3.52) and lower leptin concentrations (WMD −4.38 ng/mL, 95% CI −6.20 to −2.56; I² = 33.7%; 95% PI −8.98 to 0.21). Evidence for secondary adipokines was This is a provisional file, not the final typeset article limited. Exploratory analyses suggested a possible increase in omentin-1, whereas estimates for resistin, and retinol-binding protein 4 were imprecise, inconsistent, or both. The certainty of evidence was judged moderate for leptin and low for adiponectin.Conclusion:In individuals with clinically defined MetS, lifestyle interventions probably reduce circulating leptin and may produce a modest increase in adiponectin. The adiponectin finding warrants caution because of substantial heterogeneity and lower certainty of evidence. The clinical relevance of these biomarker changes remains uncertain, and future trials should clarify the extent to which adipokine responses are mediated by changes in body weight or adiposity.